Catalyst Event
Cogent Biosciences Inc (COGT) · Other
From KEDI U.S. Next Tech TOP10 Index (KUNTT10)
3/16/2026, 12:00:00 AM
The U.S. FDA accepted Cogent's New Drug Application (NDA) for bezuclastinib in Non-Advanced Systemic Mastocytosis (NonAdvSM) on March 16, 2026. This major regulatory milestone for a lead asset is estimated to have a ≥10% price impact, expected.
Korean Translation
2026년 3월 16일 미국 FDA가 비진행성 전신성 비만세포증(NonAdvSM) 치료제 베주클라스티닙의 신약 허가 신청(NDA)을 접수함. 주요 규제 마일스톤 달성으로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
ViaSat Inc (VSAT) · Earnings Release
Viasat is expected to release its fourth quarter and full fiscal year 2026 financial results; market impact is estimated to be low as it is a routine announcement, scheduled.
5/19/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Q1 2026 earnings release, which is estimated to have a medium impact due to typical price volatility surrounding financial reports, is scheduled.
5/14/2026, 12:00:00 AM
IonQ Inc (IONQ) · Earnings Release
Q1 2026 earnings release and company revenue guidance of $48M-$51M. Medium importance is estimated as earnings releases typically result in price movements exceeding 5% scheduled.
5/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Other
A launch for the European Space Agency's LEO-PNT pathfinder mission, which is estimated to have a low impact as a routine mission, is scheduled.
3/24/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Other
Rocket Lab announced its largest-ever launch agreement, a $190 million contract for 20 HASTE hypersonic test flights for the U.S. Department of Defense's MACH-TB 2.0 program, bringing the total backlog to over $2 billion; a high impact is estimated due to the contract size relative to annual revenue.
3/18/2026, 12:00:00 AM
Oklo Inc (OKLO) · Earnings Release
Reported Q4 2025 EPS of -$0.27 on March 17, 2026, missing analyst consensus estimates of approximately -$0.17. The company also reported a full-year 2025 operational loss of $139.3 million and provided 2026 guidance. This significant earnings miss is expected to have a moderate negative impact on the stock price.
3/17/2026, 12:00:00 AM